Chester County News and Community Website
WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has re-filed its Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for KETAFREE™, a preservative-free intravenous ketamine …
NRx Re-Files FDA Application for Preservative-Free IV Ketamine Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced it has received U.S. Food and Drug Administration (FDA) approval of a Suitability Petition allowing the company to proceed with its …
NRx Wins FDA Nod to Advance Preservative-Free Ketamine Product KETAFREE Read More WILMINGTON, DE — HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals (NASDAQ: NRXP), has completed its acquisition of Dura Medical, expanding its footprint in Florida with a focus on advanced …
HOPE Therapeutics Expands in Florida With Acquisition of Dura Medical Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that Chairman and Chief Executive Officer Jonathan Javitt, M.D., M.P.H., will participate in a fireside chat at H.C. Wainwright’s 27th Annual …
NRx Pharmaceuticals CEO to Speak at H.C. Wainwright Global Investment Conference Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that it will make its investigational therapy NRX-100, a preservative-free formulation of ketamine, available through the U.S. Food and Drug Administration’s …
NRx Pharmaceuticals Expands Access to Investigational Ketamine Therapy for Suicidal Depression Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) reported its second-quarter financial results and announced a series of significant regulatory, clinical, and corporate developments that strengthen its position in the …
NRx Pharmaceuticals Secures Expanded FDA Fast Track Designation and Strategic Investments Amid Growth Plans Read More WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) will release its second-quarter 2025 financial results after market close on Thursday, August 14, followed by a 4:30 p.m. ET conference call …
NRx Pharmaceuticals to Report Q2 2025 Results on August 14 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has achieved a significant milestone in the development of its antidepressant drug, NRX-100 (Ketamine). On September 24, 2024, the company announced that the …
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) recently received attention in an article on Psychiatrist.com, which discussed the potential of its pipeline products, NRX-100 and NRX-101, in addressing bipolar depression …
NRx Pharmaceuticals’ Innovative Treatments for Depression Gain Spotlight Read More RADNOR, PA — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has released its financial results for the second quarter and year-to-date ending June 30, 2024, along with a comprehensive business update. The company …
NRx Pharmaceuticals Reports Second Quarter and Year-to-Date 2024 Financial Results and Business Update Read More